title: [Inhaled treatments in cystic fibrosis: what's new in 2013?].
abstract: In the past few years some new inhaled drugs and inhalation devices have been proposed for the treatment of cystic fibrosis. Breath-controlled nebulizers allow increased pulmonary deposition, with a lower variability and a shorter delivery time. The new dry powder formulations of tobramycin, colistine and mannitol require a change in the inhalation technique which must be slow and deep. In the field of the inhaled mucolytic drugs, hypertonic saline and mannitol have an indication in some patients. With regard to antibiotics, dry-powder tobramycin and colistine can be substituted for the same drug delivered by nebulization. Nebulized aztreonam needs more studies to determine its place. These new treatments represent a definite advance for cystic fibrosis patients and need to be known by all practitioners. Their position in our therapeutic arsenal remains to be accurately defined.
authors.affiliation: CRCM pédiatrique, CNRS URMITE 6236, CHU Timone-Enfants, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France. Electronic address: jean-christophe.dubus@ap-hm.fr.
authors.forename: J-C
authors.initials: JC
authors.lastname: Dubus
authors.affiliation: Service de pneumologie, centre hospitalier inter-communal, 94000 Créteil, France.
authors.forename: L
authors.initials: L
authors.lastname: Bassinet
authors.affiliation: CRCM pédiatrique, hôpital Necker-Enfants-Malades, 75015 Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Chedevergne
authors.affiliation: CRCM pédiatique, hôpital Robert-Debré, 75019 Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Delaisi
authors.affiliation: CRCM adulte, hôpital Nord, 13015 Marseille, France.
authors.forename: N
authors.initials: N
authors.lastname: Desmazes-Dufeu
authors.affiliation: Service de pneumologie, cliniques universitaires Saint-Luc, 1200 Bruxelles, Belgique.
authors.forename: G
authors.initials: G
authors.lastname: Reychler
authors.affiliation: EA 6305, CEPR, DTF-Aerodrug, faculté de médecine, université François Rabelais, 37032 Tours, France.
authors.forename: L
authors.initials: L
authors.lastname: Vecellio
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000075202:Contraindications; D003550:Cystic Fibrosis / Q000188:drug therapy*; D058995:Dry Powder Inhalers; D004867:Equipment Design; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use; D005602:France; D006297:Health Services Accessibility; D006801:Humans; D008353:Mannitol / Q000008:administration & dosage / Q000627:therapeutic use; D009330:Nebulizers and Vaporizers; D011208:Powders; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D005100:Expectorants; D011208:Powders; D012462:Saline Solution, Hypertonic; D008353:Mannitol
keywords: Antibiotics; Antibiotique; Cystic fibrosis; Dispositif d’inhalation; Inhalation devices; Mucolytic agents; Mucolytiques; Mucoviscidose; Nebulization; Nébulisation